Actor Portrayal

The CDC recommends measles vaccination in certain adults born after 19571,a

aBefore 1989, people usually only received one dose of the measles vaccine or relied on natural immunity. Due to outbreaks, the CDC revised its recommendation for routine measles vaccination to a 2-dose program.2,3

Which adult populations are recommended by the CDC to get the MMR vaccine, and how many doses do they need?1

  • Adults who do not have presumptive evidence of immunityb should get at least one dose of MMR vaccine.1
  • Certain adults may need 2 doses1:
    • Adults who are going to be in a setting that poses a high risk for measles transmission should make sure they have had two total doses separated by at least 28 days. These adults include1,4:
Actor Portrayal

bPresumptive evidence of immunity can be established by written documentation of one or more doses of a measles-containing vaccine (two doses of measles-containing vaccine for school-aged children and adults at high risk), laboratory evidence of immunity, or birth before 1957.1

cHealth care personnel born before 1957 without laboratory evidence of immunity or disease should consider getting two doses of MMR vaccine.1


Measles cases and outbreaks still occur4

In the United States, where endemic measles has been declared eliminated, cases and outbreaks can still occur.5

The disease is brought into the United States by unvaccinated people who get infected in other countries. Typically, 2 out of 3 of these unvaccinated travelers are Americans. They can spread measles to other people who are not protected against measles, which can sometimes lead to outbreaks.4 Prolonged outbreaks can threaten the US measles elimination status.6

Outbreak defined as 3 or more related cases.7

Graphic Showing Number of US Adult Measles Cases in 2025 Compared to 2024Graphic Showing Number of US Adult Measles Cases in 2025 Compared to 2024

Image of Map of United States Showing Total Measles Cases by State in Adults Ages 20+ in 2025Image of Map of United States Showing Total Measles Cases by State in Adults Ages 20+ in 2025

Why is there still a risk for measles?6

Overall measles outbreak risk to the general population is low; however, measles cases have increased globally, increasing the chance of importations into the US.6

References

  1. Centers for Disease Control and Prevention. Measles Vaccination. Updated January 17, 2025. Accessed October 22, 2025. https://www.cdc.gov/measles/vaccines/index.html
  2. Centers for Disease Control (CDC). Measles prevention. MMWR Suppl. 1989;38(9):1-18.
  3. Centers for Disease Control and Prevention. Chapter 13: Measles. Last revised April 24, 2024. Accessed October 22, 2025. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-13-measles.html
  4. Plan for Travel. Centers for Disease Control and Prevention. Last Revised July 15, 2024. Accessed September 30, 2025. https://www.cdc.gov/measles/plan-for-travel.html
  5. Centers for Disease Control and Prevention. Why CDC Is Involved with Global Measles. Last revised July 14, 2025. Accessed October 22, 2025. https://www.cdc.gov/global-measles-vaccination/why/index.html
  6. Morbidity and Mortality Weekly Report (MMWR): Measles — United States, January 1, 2020–March 28, 2024. Centers for Disease Control and Prevention. Last revised April 11, 2024. Accessed September 30, 2025. https://www.cdc.gov/mmwr/volumes/73/wr/mm7314a1.htm
  7. Centers for Disease Control and Prevention. Measles cases and outbreaks. Updated October 22, 2025. Accessed October 22, 2025. https://www.cdc.gov/measles/data-research/index.html
  8. Global immunization efforts have saved at least 154 million lives over the past 50 years. World Health Organization. Last revised April 24, 2024. Accessed September 30, 2025. https://www.who.int/news/item/24-04-2024-global-immunization-efforts-have-saved-at-least-154-million-lives-over-the-past-50-years/
  9. Measles, Mumps, and Rubella FastStats. Centers for Disease Control and Prevention. Last reviewed May 13, 2025. Accessed September 30, 2025. https://cdc.gov/nchs/fastats/measles.htm
  10. Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten – United States, 2023-24 School Year. Centers for Disease Control and Prevention. Last revised October 17, 2024. Accessed September 30, 2025. https://www.cdc.gov/mmwr/volumes/73/wr/mm7341a3.htm

Indications and Usage

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.

The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.

Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.

Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.

Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.

The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R®II or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.

The following adverse reactions have been identified during the subcutaneous use of M-M-R®II or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

Dosage and administration

FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.

M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

 

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

 

Indications and Usage
Selected Safety Information

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.

The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.

Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.

Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.

Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.

The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R®II or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.

The following adverse reactions have been identified during the subcutaneous use of M-M-R®II or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

Dosage and administration

FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.

M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

 

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.